Advanced Parkinson’s disease treatment patterns in Italy: an observational study interim analysis

Abstract

Background Oral levodopa remains the mainstay of treatment for Parkinson’s disease (PD). However, as PD progresses, response to treatment may fluctuate. Managing fluctuations can be demanding for clinicians and patients. There is a paucity of real-world studies reporting on PD management in patients with fluctuations in treatment response, especially in patients with advanced stages of PD. The multicentre, observational Parkinson’s Disease Fluctuations treatment PAthway (PD-FPA) study describes the real-life management of response fluctuations in Italian patients with advanced PD. Patients and Methods PD-FPA had a retrospective and prospective phase; herein, retrospective results are presented. Ten Italian centres enrolled patients with a PD diagnosis from 10–15 years prior to study entry (T0) and who had ≥2-year history of fluctuations. Data on patient demographics, medical history, PD stage, fluctuation characteristics, symptoms, and prescribed treatments were collected at T0 and retrospectively (2 years prior to T0) via patient chart review/interview. Results Overall, 296 patients (60% male, mean age 68 years, 84% with Hoehn and Yahr scores 2–3) were enrolled. At T0, most patients (99.3%) were on oral levodopa therapy. All patients used dopaminergic medications; adjunctive medications included dopamine agonists (56%) and monoamine oxidase B (60%) and catechol-O-methyltransferase enzyme inhibitors (41%). At T0, 51% of patients had changed therapy, with response fluctuations being the most common reason (74%); wearing-off was the most common fluctuation (83%). Conclusion This interim analysis of PD-FPA suggests that adequate levodopa dosing and adjunctive medications can stabilize advanced PD and provide patients with a good quality of life.

Treatment of the early stages of Parkinson's disease. Differences in approaches to the choice of therapy in different countries

“…[6,11]. В одном из последних опубликованных исследований в Италии [12] наиболее часто назначаемыми пероральными дополнительными препаратами были сафинамид и опикапон (не зарегистрированы в России), частота назначения ингибиторов моноаминоксидазы типа В (МАО-В) составила 60%, агонисты дофаминовых рецепторов (АДР) назначались в 65% случаев. Другие исследования демонстрируют меньшую частоту назначения ингибиторов МАО-В -от 23 до 35%.…”